Aref Salah, Atia Doaa, Ramez Ahmed, Zeid Tarek Abou, Gouda Enas
Hematology Unit, Clinical Pathology Department, Mansoura University, Mansoura, Egypt.
Medical Oncology Unit, Mansoura University Oncology Center, Mansoura, Egypt.
Cancer Biomark. 2022;34(1):105-111. doi: 10.3233/CBM-210207.
Recent reports indicated the importance of chemotractant CXCL-13 in solid tumors and lymphoid malignancies. However, the prognostic value of the mentioned cytokines as biomarkers in chronic lymphocytic leukemia patient's remains to be identified. Therefore; this study was designed in order to address the relation between CXCL-13 concentrations levels and markers of severity in CLL patients.
Our study included 150 CLL patients and 20 controls. Serum CXCL-13 was determined by ELISA for CLL patients at diagnosis as well as controls.
The serum CXCL-13 levels were significantly higher in CLL patients as compared to controls. The high CXCL-13 concentration levels was significantly associated with high number of smudge cells; high LDH; high grade of Rai stage, short time to first treatment (TTT). Cox regression analysis was conducted for prediction of TTT, using age, gender, WBCs, smudge cells, CXCL-13, LDH, ZAP70, CD38, β2-microglobulin, Rai staging as covariates. High LDH, CXCL-13 and CD38% were significantly independent predictor for shorter TTT.
High CXCL-13 serum levels at CLL diagnosis is correlated with other markers of disease activity; and could be served as biomarkers that predict CLL patient's outcome.
近期报告指出趋化因子CXCL - 13在实体瘤和淋巴恶性肿瘤中的重要性。然而，上述细胞因子作为慢性淋巴细胞白血病患者生物标志物的预后价值仍有待确定。因此，本研究旨在探讨CXCL - 13浓度水平与慢性淋巴细胞白血病患者病情严重程度标志物之间的关系。
我们的研究纳入了150例慢性淋巴细胞白血病患者和20例对照。通过酶联免疫吸附测定法（ELISA）测定慢性淋巴细胞白血病患者诊断时以及对照的血清CXCL - 13水平。
与对照组相比，慢性淋巴细胞白血病患者的血清CXCL - 13水平显著更高。CXCL - 13高浓度水平与大量涂抹细胞、高乳酸脱氢酶（LDH）、高Rai分期、首次治疗时间短显著相关。使用年龄、性别、白细胞、涂抹细胞、CXCL - 13、LDH、ZAP70、CD38、β2 - 微球蛋白、Rai分期作为协变量进行Cox回归分析以预测首次治疗时间。高LDH、CXCL - 13和CD38%是首次治疗时间较短的显著独立预测因子。
慢性淋巴细胞白血病诊断时血清CXCL - 13高水平与疾病活动的其他标志物相关；并且可作为预测慢性淋巴细胞白血病患者预后的生物标志物。
